الفهرس 
List of contentsOnly 14 pages are availabe for public view
 |  | from | 80 |  |  |
| | | from | 80 | | |
Abstract
Introduction: Preeclampsia is the most common medical disorder complicating pregnancy. It is believed to be initiated by placental ischemia followed by development of endothelial dysfunction. It was demonstrated that LMWH significantly reduced the recurrence of preeclampsia in high risk women. The aim of work: The aim of this work was to assess if there was a possible role of LMWH in the management of cases of preeclampsia. Research Plan: The study was conducted over a period of 30 months on 100 primigravida women diagnosed with preeclampsia at MUH divided in 2 groups each containing 50 cases. LMWH was given to the study group beside the usual regimen of preeclampsia. The control group received the usual regimen of preeclampsia only. At the start of the study demographic data were recorded for both groups. Antenatal and postnatal follow up was done for both mother and fetus. Results: LMWH improved systolic & diastolic blood pressures, umbilical artery doppler indices and perinatal mortality in preeclamptic ladies when used beside the usual line of treatment. Conclusion: Use of LMWH beside the usual line of treatment in preeclamptic ladies improved maternal blood pressure, umbilical artery doppler indices and perinatal mortality, so it is recommended to use it in high risk cases and in early diagnosed cases of preeclampsia. It is important to weigh benefits versus risks in using LMWH in the management of established preeclampsia cases especially when diagnosis of preeclampsia is late in pregnancy.